Regeneron

Business

Regeneron Aims to Redefine Obesity Treatment with Dual-Action Drug Targeting Weight and Cholesterol

Regeneron Pharmaceuticals is positioning its experimental obesity drug, olatorepatide, as a potential game-changer by combining significant weight loss with a dramatic reduction in 'bad' cholesterol. The company believes this dual benefit could carve out a unique niche in the competitive $150 billion market, currently led by Novo Nordisk and Eli Lilly.

Business

Regeneron Caps 2025 with Strong Quarter, Eyes Pipeline Expansion Amid EYLEA Transition

Regeneron Pharmaceuticals reported a steady finish to 2025, driven by growth in key drugs Dupixent and EYLEA HD. While navigating competitive pressures on its legacy blockbuster, the biotech giant outlined an ambitious 2026 strategy focused on regulatory milestones and a broad clinical pipeline.

Business

Regeneron's Stock Slump: A Buying Opportunity or a Sign of Deeper Trouble?

Regeneron Pharmaceuticals' shares have softened in recent weeks, lagging behind broader market gains. A deep dive into valuation metrics, including DCF analysis and P/E ratios, suggests the biotech giant may be significantly undervalued. We examine the numbers behind the headlines and what they mean for investors.

Business

Amgen Earnings Preview: Biotech Giant Faces Growth Test Amid Market Scrutiny

As Amgen prepares to release its fourth-quarter results, investors are watching for signs of sustained momentum in its key drug portfolios and the impact of recent acquisitions.

Business

Amid Steep Decline, $24 Million Bet Highlights Faith in FactSet's Enduring Data Model

As FactSet's stock price fell 45% over the past year, investment firm McDonald Capital Investors made a significant $24 million purchase, underscoring a long-term conviction in the financial data provider's resilient, high-margin subscription business.